ARS Pharmaceuticals Newsroom

ARS Pharmaceuticals Launches NeffyinSchools Program

TipRanksJan 21 08:10 ET

Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)

TipRanksJan 15 05:30 ET · Ratings

ARS Pharmaceuticals Price Target Raised to $28.00/Share From $26.00 by Raymond James

Dow JonesJan 14 12:45 ET · Ratings

Raymond James Maintains Strong Buy on ARS Pharmaceuticals, Raises Price Target to $28

BenzingaJan 14 12:35 ET · Ratings

Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $28

Moomoo NewsJan 14 09:31 ET · Ratings

ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow JonesJan 13 11:26 ET · Ratings

ARS Pharmaceuticals Analyst Ratings

BenzingaJan 13 11:15 ET · Ratings

Express News | Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'revenue', and Removes Reference to Estimate)

ReutersJan 13 10:32 ET

ARS Pharmaceuticals Lays Down 2025 Objectives for Epinephrine Nasal Spray

Seeking AlphaJan 13 09:50 ET

ARS Pharmaceuticals Highlights Success and Plans for 2025

TipRanksJan 13 08:43 ET

ARS Pharma Announces Preliminary Q4 2024 Results With Neffy Revenue At $6.5M; 14.5K Units Delivered. Cash Reserves At $314M To Fund Operations For 3 Years; 2025 Strategy Includes Expanding Neffy Access, Increasing Awareness, And Seeking FDA Approval...

BenzingaJan 13 08:23 ET

ARS Pharmaceuticals | 8-K: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy ® (epinephrine nasal spray)

SECJan 13 08:12 ET · Announcements

Express News | ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $27 From $26

ReutersJan 13 08:01 ET

Express News | ARS Pharmaceuticals Q4 Revenue USD 6.5 Million Vs. IBES Estimate USD 17 Million

ReutersJan 13 08:00 ET

Press Release: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for Neffy(R) (Epinephrine Nasal Spray)

Dow JonesJan 13 08:00 ET

Insider Sale: Director at $SPRY (SPRY) Sells 50,000 Shares

Quiver QuantitativeJan 7 18:31 ET

ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

MT NewswiresJan 6 11:06 ET

Institutional Investors May Overlook ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Recent US$56m Market Cap Drop as Long-term Gains Remain Positive

Simply Wall StDec 31, 2024 08:02 ET

ARS Pharmaceuticals Says Express Scripts Has Added Neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

BenzingaDec 19, 2024 17:29 ET

ARS Pharmaceuticals Announces Neffy (Epinephrine Nasal Spray) Is Available on Express Scripts Commercial National Formularies

GlobeNewswireDec 19, 2024 17:25 ET